# A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Study · id `cardio:ct-nct01755156` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01755156](<https://clinicaltrials.gov/study/NCT01755156>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01755156

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

## Technical summary

Registry record NCT01755156. Randomized; triple masking; primary purpose treatment. Start 2013-01-11 (actual); primary completion 2016-03-16 (actual). Results posted on 2017-03-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 402 participants (enrolled count; ClinicalTrials.gov record NCT01755156, source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)
- Started: 2013-01-11 (actual) (ClinicalTrials.gov record NCT01755156, source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2016-03-16 (actual) (ClinicalTrials.gov record NCT01755156, source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)
- Completion: 2016-03-16 (actual) (ClinicalTrials.gov record NCT01755156, source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2017-03-20 (ClinicalTrials.gov record NCT01755156, source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01755156-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Matching placebo to omarigliptin
- Intervention (Drug): Glimepiride
- Intervention (Drug): Matching placebo to glimepiride
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy (`cardio:pubmed-28547998`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 03b76d8c400283375ccd419724fa034de7b2b9760025562dce1e2ab9cbde7d2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
